1. 805PA phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. (23rd October 2018) Authors: Fizazi, K; Hussain, M; Saad, F; Shore, N; De Giorgi, U; Efstathiou, E; Ferreira, U; Ivashchenko, P; Madziarska, K; Al-Adhami, M; Modelska, K; Phung, D; Steinberg, J; Sternberg, C N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 807PProlonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study. (23rd October 2018) Authors: Tombal, B; Hussain, M; Penson, D; Attard, G; Sternberg, C N; Phung, D; Morlock, R; Modelska, K; Ramaswamy, K; Ivanescu, C; Saad, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗